Antoine Italiano1, Olivier Mir2, Simone Mathoulin-Pelissier3, Nicolas Penel4, Sophie Piperno-Neumann5, Emmanuelle Bompas6, Christine Chevreau7, Florence Duffaud8, Natacha Entz-Werlé9, Esma Saada10, Isabelle Ray-Coquard11, Cyril Lervat12, Nathalie Gaspar13, Perrine Marec-Berard14, Hélène Pacquement15, John Wright16, Maud Toulmonde17, Alban Bessede18, Amandine Crombe19, Michèle Kind18, Carine Bellera20, Jean-Yves Blay11. 1. Early Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux, France; University of Bordeaux, Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr. 2. Department of Medicine, Institut Gustave Roussy, Villejuif, France. 3. Unité d'épidémiologie et de recherche cliniques, Institut Bergonié, Bordeaux, France; Inserm UMR 1219, Équipe Epicene, Bordeaux, France; Inserm CIC-EC 1401, Bordeaux, France. 4. Department of Medical Oncology, Centre Oscar Lambret, University of Lille, Lille, France. 5. Department of Medicine, Institut Curie, Paris, France. 6. Department of Medicine, Institut Cancerologie de l'Ouest, Nantes, France. 7. Department of Medicine, Oncopole, Toulouse, France. 8. Department of Medical Oncology, Assistance Publique des Hôpitaux de Marseille, Hôpital La Timone, Marseille, France. 9. Department of Tumor Pediatrics, University Hospital Centre of Strasbourg, Strasbourg, France. 10. Department of Medicine, Centre Antoine Lacassagne, Nice, France. 11. Department of Medicine, Centre Leon Berard, Lyon, France. 12. Department of Tumor Pediatrics, Centre Oscar Lambret, University of Lille, Lille, France. 13. Department of Tumor Pediatrics, Institut Gustave Roussy, Villejuif, France. 14. Department of Tumor Pediatrics, Centre Leon Berard, Lyon, France. 15. Department of Tumor Pediatrics, Institut Curie, Paris, France. 16. Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. 17. Early Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux, France. 18. Immusmol, Bordeaux, France. 19. Department of Imaging, Institut Bergonié, Bordeaux, France. 20. Unité d'épidémiologie et de recherche cliniques, Institut Bergonié, Bordeaux, France; Inserm CIC-EC 1401, Bordeaux, France.
Abstract
BACKGROUND: Patients with Ewing sarcoma or osteosarcoma have a median overall survival of less than 12 months after diagnosis, and a standard treatment strategy has not yet been established. Pharmacological inhibition of MET signalling and aberrant angiogenesis has shown promising results in several preclinical models of Ewing sarcoma and osteosarcoma. We aimed to investigate the activity of cabozantinib, an inhibitor of MET and VEGFR2, in patients with advanced Ewing sarcoma and osteosarcoma. METHODS: We did a multicentre, single-arm, two-stage, phase 2 trial in patients with advanced Ewing sarcoma or osteosarcoma recruited from ten centres in the French Sarcoma Group. Key eligibility criteria were aged 12 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and documented disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1) before study entry. The number of previous lines of treatment was not limited. Patients received cabozantinib (adults 60 mg, children [<16 years] 40 mg/m2) orally once daily in 28-day cycles until disease progression, unacceptable toxicity, the investigator's decision to discontinue, or participant withdrawal. The primary endpoint for Ewing sarcoma was best objective response within 6 months of treatment onset; for osteosarcoma, a dual primary endpoint of 6-month objective response and 6-month non-progression was assessed. All enrolled patients who received at least one dose of cabozantinib were included in the safety analysis, and all participants who received at least one complete or two incomplete treatment cycles were included in the efficacy population. This study was registered with ClinicalTrials.gov, number NCT02243605. FINDINGS: Between April 16, 2015, and July 12, 2018, 90 patients (45 with Ewing sarcoma 45 with osteosarcoma) were recruited to the study. Median follow-up was 31·3 months (95% CI 12·4-35·4) for patients with Ewing sarcoma and 31·1 months (24·4-31·7) for patients with osteosarcoma. 39 (87%) patients with Ewing sarcoma and 42 (93%) patients with osteosarcoma were assessable for efficacy after histological and radiological review. In patients with Ewing sarcoma, ten (26%; 95% CI 13-42) of 39 patients had an objective response (all partial responses) by 6 months; in patients with osteosarcoma, five (12%; 4-26) of 42 patients had an objective response (all partial responses) and 14 (33%; 20-50) had 6-month non-progression. The most common grade 3 or 4 adverse events were hypophosphataemia (five [11%] for Ewing sarcoma, three [7%] for osteosarcoma), aspartate aminotransferase increase (two [4%] for Ewing sarcoma, three [7%] for osteosarcoma), palmar-plantar syndrome (three [7%] for Ewing sarcoma, two [4%] for osteosarcoma), pneumothorax (one [2%] for Ewing sarcoma, four [9%] for osteosarcoma), and neutropenia (two [4%] for Ewing sarcoma, four [9%] for osteosarcoma). At least one serious adverse event was reported in 61 (68%) of 90 patients. No patients died from drug-related toxic effects. INTERPRETATION: Cabozantinib has antitumor activity in patients with advanced Ewing sarcoma and osteosarcoma and was generally well tolerated. Cabozantinib could represent a new therapeutic option in this setting, and deserves further investigation. FUNDING: Institut Bergonié; French National Cancer Institute; Association pour la Recherche contre le Cancer.
BACKGROUND: Patients with Ewing sarcoma or osteosarcoma have a median overall survival of less than 12 months after diagnosis, and a standard treatment strategy has not yet been established. Pharmacological inhibition of MET signalling and aberrant angiogenesis has shown promising results in several preclinical models of Ewing sarcoma and osteosarcoma. We aimed to investigate the activity of cabozantinib, an inhibitor of MET and VEGFR2, in patients with advanced Ewing sarcoma and osteosarcoma. METHODS: We did a multicentre, single-arm, two-stage, phase 2 trial in patients with advanced Ewing sarcoma or osteosarcoma recruited from ten centres in the French Sarcoma Group. Key eligibility criteria were aged 12 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and documented disease progression (according to Response Evaluation Criteria in Solid Tumors version 1.1) before study entry. The number of previous lines of treatment was not limited. Patients received cabozantinib (adults 60 mg, children [<16 years] 40 mg/m2) orally once daily in 28-day cycles until disease progression, unacceptable toxicity, the investigator's decision to discontinue, or participant withdrawal. The primary endpoint for Ewing sarcoma was best objective response within 6 months of treatment onset; for osteosarcoma, a dual primary endpoint of 6-month objective response and 6-month non-progression was assessed. All enrolled patients who received at least one dose of cabozantinib were included in the safety analysis, and all participants who received at least one complete or two incomplete treatment cycles were included in the efficacy population. This study was registered with ClinicalTrials.gov, number NCT02243605. FINDINGS: Between April 16, 2015, and July 12, 2018, 90 patients (45 with Ewing sarcoma 45 with osteosarcoma) were recruited to the study. Median follow-up was 31·3 months (95% CI 12·4-35·4) for patients with Ewing sarcoma and 31·1 months (24·4-31·7) for patients with osteosarcoma. 39 (87%) patients with Ewing sarcoma and 42 (93%) patients with osteosarcoma were assessable for efficacy after histological and radiological review. In patients with Ewing sarcoma, ten (26%; 95% CI 13-42) of 39 patients had an objective response (all partial responses) by 6 months; in patients with osteosarcoma, five (12%; 4-26) of 42 patients had an objective response (all partial responses) and 14 (33%; 20-50) had 6-month non-progression. The most common grade 3 or 4 adverse events were hypophosphataemia (five [11%] for Ewing sarcoma, three [7%] for osteosarcoma), aspartate aminotransferase increase (two [4%] for Ewing sarcoma, three [7%] for osteosarcoma), palmar-plantar syndrome (three [7%] for Ewing sarcoma, two [4%] for osteosarcoma), pneumothorax (one [2%] for Ewing sarcoma, four [9%] for osteosarcoma), and neutropenia (two [4%] for Ewing sarcoma, four [9%] for osteosarcoma). At least one serious adverse event was reported in 61 (68%) of 90 patients. No patients died from drug-related toxic effects. INTERPRETATION: Cabozantinib has antitumor activity in patients with advanced Ewing sarcoma and osteosarcoma and was generally well tolerated. Cabozantinib could represent a new therapeutic option in this setting, and deserves further investigation. FUNDING: Institut Bergonié; French National Cancer Institute; Association pour la Recherche contre le Cancer.
Authors: Sarah E S Leary; Amy W Wozniak; Catherine A Billups; Jianrong Wu; Valerie McPherson; Michael D Neel; Bhaskar N Rao; Najat C Daw Journal: Cancer Date: 2013-04-26 Impact factor: 6.860
Authors: Lara E Davis; Vanessa Bolejack; Christopher W Ryan; Kristen N Ganjoo; Elizabeth T Loggers; Sant Chawla; Mark Agulnik; Michael B Livingston; Damon Reed; Vicky Keedy; Daniel Rushing; Scott Okuno; Denise K Reinke; Richard F Riedel; Steven Attia; Leo Mascarenhas; Robert G Maki Journal: J Clin Oncol Date: 2019-04-23 Impact factor: 44.544
Authors: Emmy D G Fleuren; Melissa H S Roeffen; William P Leenders; Uta E Flucke; Myrella Vlenterie; Hendrik W Schreuder; Otto C Boerman; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers Journal: Int J Cancer Date: 2013-02-25 Impact factor: 7.396
Authors: Bruce Sabath; Hasan A Muhammad; Amulya Balagani; David E Ost; Erik Vakil; Tahreem Ahmed; Macarena R Vial; Horiana B Grosu Journal: BMC Cancer Date: 2018-10-01 Impact factor: 4.430
Authors: Fiorela N Hernandez Tejada; Alejandro Zamudio; Mario L Marques-Piubelli; Branko Cuglievan; Douglas Harrison Journal: Curr Oncol Rep Date: 2020-11-16 Impact factor: 5.075
Authors: Brian Schulte; Nisha Mohindra; Mohammed Milhem; Steven Attia; Steven Robinson; Varun Monga; Angela C Hirbe; Peter Oppelt; John Charlson; Irene Helenowski; Susan Abbinanti; Rasima Cehic; Scott Okuno; Brian A Van Tine; Mark Agulnik Journal: Br J Cancer Date: 2021-05-28 Impact factor: 9.075
Authors: Sarah B Whittle; Katharine Offer; Ryan D Roberts; Amy LeBlanc; Cheryl London; Robbie G Majzner; Alex Y Huang; Peter Houghton; E Alejandro Sweet Cordero; Patrick J Grohar; Michael Isakoff; Michael W Bishop; Elizabeth Stewart; Emily K Slotkin; Emily Greengard; Scott C Borinstein; Fariba Navid; Richard Gorlick; Katherine A Janeway; Damon R Reed; Pooja Hingorani Journal: Pediatr Blood Cancer Date: 2021-06-16 Impact factor: 3.838